Abstract Number: 2688 • ACR Convergence 2024
HLA-DRB4: A Novel Susceptibility Locus in Systemic Sclerosis Patients with Severe Calcinosis
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease. Class II HLA alleles have been reported to play an important role in SSc pathogenesis. Calcinosis, deposition of…Abstract Number: 2625 • ACR Convergence 2024
Brain Injury Markers Correlate with Impaired Executive Function and Disease Activity in Children with Systemic Lupus Erythematosus
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) commonly experience impaired executive function (EF), and attribution to neuropsychiatric lupus (NPSLE) is challenging. Serum markers of…Abstract Number: 2514 • ACR Convergence 2024
The Pattern of Renal Involvement in Relapsing Cryoglobulinemic Vasculitis After Successful Sustained Viral Response by Direct-Acting Antiviral Treatments
Background/Purpose: Interferon-free Direct Acting Antiviral (DAA) treatments proved to be effective for the treatment of HCV-induced Cryoglobulinemic Vasculitis (HCV-Cryovas). Some reports showed relapses of HCV-Cryovas…Abstract Number: 2681 • ACR Convergence 2024
Association of Social Determinants of Health with Systemic Lupus Erythematosus in the United States: Nationally Representative Estimates for 2017-2021
Background/Purpose: Careful assessment of individuals’ social determinants of health (SDOH) that affect systemic lupus erythematosus (SLE) is crucial, as such evidence will improve care and…Abstract Number: PP07 • ACR Convergence 2024
My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective
Background/Purpose: Since my diagnosis with diffuse scleroderma and ILD, I have balanced the roles of patient and young pharmacist. A duality that has surely impacted…Abstract Number: PP04 • ACR Convergence 2024
Involving Pediatric Patients in Their Own Care
Background/Purpose: When I was 14, I was diagnosed with thrombocytopenia, which led to more testing and a diagnosis of systemic lupus erythematosus (SLE). As a…Abstract Number: 2510 • ACR Convergence 2024
The Effect of Coronary Artery Aneurysms and IVIG Use on Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited…Abstract Number: PP14 • ACR Convergence 2024
Support Groups and Chronic Illness: Finding Social Support Among Peers
Background/Purpose: Like many lupus patients, my journey has been long, complex, and difficult. I began experiencing symptoms in 2019. Over the next five years, I…Abstract Number: 2646 • ACR Convergence 2024
Rare Variants in the IL1RAP Gene Implicate the IL-1 Signaling Pathway in the Pathogenesis of Systemic Sclerosis in African and European Ancestries
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by systemic inflammation and fibrosis. Interleukin-1 receptor accessory protein (IL1RAP) is a co-receptor for the Interleukin-1…Abstract Number: 2662 • ACR Convergence 2024
In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
Background/Purpose: CAR T cell therapy promises to revolutionize the treatment of hematologic malignancies, and more recently has generated early data that it may afford long…Abstract Number: 2485 • ACR Convergence 2024
Orbital Pseudotumor in Granulomatosis with Polyangiitis. Interim Analysis of Clinical Outcomes from a European Collaborative Observational Study
Background/Purpose: Orbital Pseudotumor (OPT) is a rare organ-threatening manifestation of Granulomatosis with Polyangiitis (GPA), with severe prognosis and historically refractory to most treatments. This is…Abstract Number: 2482 • ACR Convergence 2024
Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies
Background/Purpose: The 52-week Phase III MIRRA trial demonstrated the safety and efficacy of anti-IL-5 mepolizumab in patients with EGPA. However, longer-term safety data are limited.…Abstract Number: 2478 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are subtypes of ANCA-associated vasculitis that frequently involve the kidneys. However, a subset of patients with…Abstract Number: 2505 • ACR Convergence 2024
C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?
Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is an inflammatory disease caused by the accumulation of immune complexes of IgA in the walls of small blood vessels…Abstract Number: 2512 • ACR Convergence 2024
French Multicenter Retrospective Study of Patients with Cocaine- and/or Levamisole-induced Vasculitis and Vasculopathy
Background/Purpose: Levamisole, an imidazothiazole formerly used as an anthelmintic, is also used as a cutting agent to enhance the effects and duration of cocaine. In…
- « Previous Page
- 1
- …
- 198
- 199
- 200
- 201
- 202
- …
- 2607
- Next Page »
